David J. Maloney
YOU?
Author Swipe
View article: 12-Lipoxygenase (12-LOX) Plays a Key Role in Hyperinflammatory Response Caused by SARS-CoV-2
12-Lipoxygenase (12-LOX) Plays a Key Role in Hyperinflammatory Response Caused by SARS-CoV-2 Open
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to significant global morbidity and mortality. The severe disease outcomes are often linked to a hyperinflammatory response known as a “cytokine storm.” The underlying mechanis…
View article: KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage
KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage Open
Basal breast cancer is a subtype with a poor prognosis in need of more effective therapeutic approaches. Here we describe a unique role for the KDM4C histone lysine demethylase in KDM4C -amplified basal breast cancers, where KDM4C inhibiti…
View article: 12-Lipoxygenase inhibition improves glucose homeostasis and obesity-associated inflammation in human gene replacement mice
12-Lipoxygenase inhibition improves glucose homeostasis and obesity-associated inflammation in human gene replacement mice Open
Obesity-associated inflammation is characterized by macrophage infiltration into peripheral tissues, contributing to the progression of prediabetes and type 2 diabetes (T2D). The enzyme 12-lipoxygenase (12-LOX) catalyzes the formation of p…
View article: 12-Lipoxygenase inhibition delays onset of autoimmune diabetes in human gene replacement mice
12-Lipoxygenase inhibition delays onset of autoimmune diabetes in human gene replacement mice Open
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing β cells and involves an interplay between β cells and cells of the innate and adaptive immune systems. We investigated the therapeutic potential of t…
View article: 12-Lipoxygenase inhibition delays onset of autoimmune diabetes in human gene replacement mice
12-Lipoxygenase inhibition delays onset of autoimmune diabetes in human gene replacement mice Open
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing β cells and involves an interplay between β cells and cells of the innate and adaptive immune systems. We investigated the therapeutic potential of t…
View article: SAT071 Inhibition Of 12 Lipoxygenase In A Humanized Mouse Model Of Type 1 Diabetes Delays Progression Of Hyperglycemia
SAT071 Inhibition Of 12 Lipoxygenase In A Humanized Mouse Model Of Type 1 Diabetes Delays Progression Of Hyperglycemia Open
Disclosure: T. Nargis: None. A. Chakraborty: None. K. Figatner: None. D. Maloney: None. M. Boxer: None. S.A. Tersey: None. R.G. Mirmira: None. Type 1 diabetes (T1D) is an autoimmune disorder characterized by islet inflammation (insulitis).…
View article: OC 14.3 A Novel Strategy to Combat the Procoagulant Phenotype in Immune Thrombotic Thrombocytopenia using 12-LoX Inhibition
OC 14.3 A Novel Strategy to Combat the Procoagulant Phenotype in Immune Thrombotic Thrombocytopenia using 12-LoX Inhibition Open
Background: Immune thrombotic thrombocytopenia (ITT) disorders, including heparin-induced thrombocytopenia (HIT), are caused by IgG immune complexes that activate platelets through Fc Receptor for IgG IIA (FcγRIIA).ITTs, characterized by p…
View article: Supplementary Table 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors
Supplementary Table 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
PDF - 65K, IC50 value table.
View article: Supplementary Materials and Methods from Biochemical Assays for the Discovery of TDP1 Inhibitors
Supplementary Materials and Methods from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
PDF - 89K, Supplementary Materials and Methods.
View article: Supplementary Figure 2 from Biochemical Assays for the Discovery of TDP1 Inhibitors
Supplementary Figure 2 from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
PDF - 188K, Suface Plasmon Resonance (SPR) profiles binding for JLT048 and NCGC00183674 to recombinant TDP1 bound to the surface.
View article: Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific tumor types by testin…
View article: Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 4.
View article: Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 5.
View article: Data from Biochemical Assays for the Discovery of TDP1 Inhibitors
Data from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
Drug screening against novel targets is warranted to generate biochemical probes and new therapeutic drug leads. TDP1 and TDP2 are two DNA repair enzymes that have yet to be successfully targeted. TDP1 repairs topoisomerase I–, alkylation-…
View article: Supplementary Materials and Methods from Biochemical Assays for the Discovery of TDP1 Inhibitors
Supplementary Materials and Methods from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
PDF - 89K, Supplementary Materials and Methods.
View article: Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
File contains synthesis of CN210, sequences for siRNAs, supplementary tables 1 to 3, supplementary figures 1 through 8 and figure legends.
View article: Supplementary Table 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors
Supplementary Table 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
PDF - 65K, IC50 value table.
View article: Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
File contains synthesis of CN210, sequences for siRNAs, supplementary tables 1 to 3, supplementary figures 1 through 8 and figure legends.
View article: Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific tumor types by testin…
View article: Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 5.
View article: Supplementary Figure 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors
Supplementary Figure 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
PDF - 119K, Schematic representation of the AlphaScreen 3'-phospho-tyrosine DNA substrate used in the TDP1 qHTS assay.
View article: Supplementary Figure 2 from Biochemical Assays for the Discovery of TDP1 Inhibitors
Supplementary Figure 2 from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
PDF - 188K, Suface Plasmon Resonance (SPR) profiles binding for JLT048 and NCGC00183674 to recombinant TDP1 bound to the surface.
View article: Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 4.
View article: Data from Biochemical Assays for the Discovery of TDP1 Inhibitors
Data from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
Drug screening against novel targets is warranted to generate biochemical probes and new therapeutic drug leads. TDP1 and TDP2 are two DNA repair enzymes that have yet to be successfully targeted. TDP1 repairs topoisomerase I–, alkylation-…
View article: Supplementary Figure 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors
Supplementary Figure 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors Open
PDF - 119K, Schematic representation of the AlphaScreen 3'-phospho-tyrosine DNA substrate used in the TDP1 qHTS assay.
View article: Supplementary Figures 1-5, Tables 1-2 from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
Supplementary Figures 1-5, Tables 1-2 from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature Open
Supplementary Figures 1-5, Tables 1-2 from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
View article: Data from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
Data from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature Open
Ingenol-3-angelate (Ing3A), extracted from Euphorbia peplus, is currently in clinical trials for eradicating basal cell carcinoma, actinic keratosis, and squamous cell carcinoma (SCC) in situ by topical application. Although …
View article: Supplementary Figures 1-5, Tables 1-2 from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
Supplementary Figures 1-5, Tables 1-2 from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature Open
Supplementary Figures 1-5, Tables 1-2 from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
View article: Data from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
Data from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature Open
Ingenol-3-angelate (Ing3A), extracted from Euphorbia peplus, is currently in clinical trials for eradicating basal cell carcinoma, actinic keratosis, and squamous cell carcinoma (SCC) in situ by topical application. Although …
View article: A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2
A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2 Open